Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period
Authors:
- Ekaterina I. AlexeevaEAEkaterina I. Alexeeva
- Tatiana M. DvoryakovskayaTDTatiana M. Dvoryakovskaya
- Irina P. NikishinaINIrina P. Nikishina
- Elena S. ZholobovaEZElena S. Zholobova
- Valeriya G. MatkavaVMValeriya G. Matkava
- Elizaveta A. KrekhovaEKElizaveta A. Krekhova
- Rinat K. RaupovRRRinat K. Raupov
- Daria V. BukhanovaDBDaria V. Bukhanova
- Alina N. EgorovaAEAlina N. Egorova
- Sergey A. GrishinSGSergey A. Grishin
- Mikhail Yu. SamsonovMSMikhail Yu. Samsonov
- Mikhail M. KostikMikhail M. Kostik
Open Access
- 30 December 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 79
Abstract
Background/Objectives: This study aimed to evaluate the pharmacokinetics (PK), effectiveness, and safety of the direct interleukin-6 (IL-6) inhibitor olokizumab (OKZ) in adolescent patients with active polyarticular juvenile idiopathic arthritis (pJIA) who had an inadequate response or intolerance to methotrexate (MTX). Methods: We analyzed results from an open-label, single-arm trial of OKZ therapy at a dose of 64 mg every 4 weeks for 24 weeks. We evaluated pharmacokinetic (PK) parameters, clinical effectiveness, serum C-reactive protein (CRP) dynamics, and adverse events (AEs). Results: Sixteen patients were included in the study, of whom 13 (81.2%) received OKZ through Week 24. The PK profile was consistent with observations in adults with rheumatoid arthritis (RA). By Week 16, 12 (80%) patients achieved an ACRpedi30 response, 11 (73.3%) achieved an ACRpedi50 response, and 2 (13.3%) reached inactive disease status. This response was sustained through Week 24, and no disease flares were observed. A trend toward a better response was noted among patients with baseline CRP > 10 mg/L, higher baseline IL-6, and those naïve to biologic DMARDs. Twelve patients (75.0%) experienced twenty-three mild or moderate AEs. Infections were the most frequent AEs (in 6 patients, 37.5%). No serious AEs or deaths occurred. Conclusions: OKZ treatment reduced pJIA disease activity and was well tolerated. The safety profile was consistent with that of other IL-6 inhibitors, and the PK profile matched that seen in adult RA patients.Keywords
Funding Information
- R-Pharm International LLC
This publication has 31 references indexed in Scilit:
- Clinical outcomes of tocilizumab therapy in polyarticular and systemic juvenile idiopathic arthritis: a single-center analysis (2018-2022)Rheumatology International, 2024
- Olokizumab versus Placebo or Adalimumab in Rheumatoid ArthritisNew England Journal of Medicine, 2022
- Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic ArthritisArthritis & Rheumatology, 2021
- Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III TrialArthritis & Rheumatology, 2020
- Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity ScoreAnnals of the Rheumatic Diseases, 2014
- Advances from clinical trials in juvenile idiopathic arthritisNature Reviews Rheumatology, 2013
- Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterAnnals of the Rheumatic Diseases, 2013
- Development and validation of a composite disease activity score for juvenile idiopathic arthritisArthritis Care & Research, 2009
- Juvenile idiopathic arthritisThe Lancet, 2007
- Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritisClinical and Experimental Immunology, 1994